| Predicate |
Object |
| contentType |
Journal Article|Review |
| endingPage |
10; discussion 49 |
| issn |
1464-410X
1464-4096 |
| issueIdentifier |
s2 |
| pageRange |
7-10; discussion 49 |
| publicationName |
BJU International |
| startingPage |
7 |
| bibliographicCitation |
Takenaka T. Classical vs reverse pharmacology in drug discovery. BJU Int. 2001 Sep;88 Suppl 2():7–10; discussion 49. doi: 10.1111/j.1464-410x.2001.00112.x. PMID: 11589663. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a8a5d14b652890c1e613895197732492 |
| date |
200109 |
| identifier |
https://doi.org/10.1111/j.1464-410x.2001.00112.x
https://pubmed.ncbi.nlm.nih.gov/11589663 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1464-4096
https://portal.issn.org/resource/ISSN/1464-410X
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21363 |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Classical vs reverse pharmacology in drug discovery |
| discusses |
http://id.nlm.nih.gov/mesh/M0000493
http://id.nlm.nih.gov/mesh/M0020790
http://id.nlm.nih.gov/mesh/M0234193 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D013449Q000494
http://id.nlm.nih.gov/mesh/D000317Q000494 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D013449Q000737
http://id.nlm.nih.gov/mesh/D002626
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D015195
http://id.nlm.nih.gov/mesh/D000077409
http://id.nlm.nih.gov/mesh/D000317Q000737 |